Home » Stocks » CBLI

Cleveland BioLabs, Inc. (CBLI)

Stock Price: $4.03 USD 0.29 (7.75%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
Market Cap 51.94M
Revenue (ttm) 631,842
Net Income (ttm) -2.41M
Shares Out 13.00M
EPS (ttm) -0.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $4.03
Previous Close $3.74
Change ($) 0.29
Change (%) 7.75%
Day's Open 3.81
Day's Range 3.81 - 4.43
Day's Volume 924,545
52-Week Range 1.09 - 4.43


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 3 weeks ago

NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cleveland BioLabs, Inc. (NASDAQ: CBLI) conce...

PRNewsWire - 2 months ago

NEW YORK, Oct. 21, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cleveland BioLabs, Inc. ("CBL...

PRNewsWire - 2 months ago

NEW YORK, Oct. 21, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Cleveland BioLabs, Inc. (NASDAQ: CBLI) and its board of directors concerning the...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Cytocom, Inc. is fair to ...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 20, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Cleveland BioLabs, Inc. ("B...

Benzinga - 11 months ago

Shares of nano-cap Cleveland BioLabs, Inc. (NASDAQ: CBLI) jumped out of the gate at Monday's open and are sustaining the strong momentum on over 100 times their average volume.

Benzinga - 11 months ago

Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.

Other stocks mentioned: AEMD, APT, AZN, BCRX, CERS, CODX, INO, LAKE, MRNA, NNVC, NVAX, VIR

About CBLI

Cleveland BioLabs, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-r... [Read more...]

IPO Date
Jul 21, 2006
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2019, CBLI's revenue was $1.11 million, a decrease of -2.18% compared to the previous year's $1.14 million. Losses were -$2.65 million, -26.72% less than in 2018.

Financial Statements